Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 18 2025
0mins
Should l Buy ?
Source: Benzinga
Stock Performance and Delisting: BrainStorm Cell Therapeutics Inc. (BCLI) shares plummeted 42.74% to $0.67 after the company announced its voluntary delisting from the Nasdaq due to non-compliance with shareholder equity requirements, although it will continue trading on the OTCQB Venture Market.
Company's Commitment: Despite the delisting, CEO Chaim Lebovits reassured shareholders that the company's mission to develop its ALS therapy, NurOwn, remains unchanged, emphasizing ongoing research and business operations are unaffected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
